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PROFIL KLINIKAL DAN HEMATOLOGI DI KALANGAN PESAKIT BETA 
TALASEMIA YANG MEMERLUKAN TRANFUSI DARAH SECARA 
BERKALA DAN TIDAK BERKALA DI NEGERI KEDAH 
ABSTRAK 
Pengenalan: Beta (β) talasemia adalah penyakit berkaitan hemoglobin yang disebabkan 
oleh pengurangan atau ketiadaan β globin. Individu dengan β talasemia boleh menjadi 
heterozigot, heterozigot kompaun, atau homozigot serta boleh mempunyai interaksi 
dengan hemoglobinopati lain. Kedah mempunyai kadar pesakit talasemia yang tinggi 
dengan kadar 20.25 di dalam 100 000 penduduk. Mutasi yang berbeza dalam gen globin 
β menyebabkan kepelbagaian di dalam ciri-ciri klinikal pesakit β talasemia. Oleh itu, 
pengenalpastian genotip adalah penting untuk kaunseling. Objektif: Untuk menentukan 
profil klinikal, hematologi dan β mutasi pesakit β talasemia di Kedah. Kaedah: 100 
pesakit β talasemia dikenalpasti melalui sistem maklumat hospital. Rekod sejarah beserta 
laporan makmal direkodkan. Untuk kajian mutasi β talasemia, pengesanan terhadap 20 
jenis mutasi dijalankan melalui kaedah M-ARMS. Keputusan kajian dan perbincangan: 
Daripada 100 pesakit yang dikaji, 66% daripada mereka adalah pesakit yang bergantung 
kepada transfusi darah secara berkala (TDT) manakala 34% adalah tidak bergantung 
kepada transfusi darah secara berkala (NTDT). Dalam kajian ini, pesakit TDT didiagnos 
pada purata usia yang lebih muda 2.75 (2.28) tahun berbanding dengan pesakit NTDT, 
iaitu pada purata umur 19.87 (17.87) tahun. Pesakit TDT juga didapati mepunyai lebih 
kadar tumbesaran yang terencat dan kadar pembesaran limpa yang lebih signifikan 
berbanding dengan pesakit β talasemia NTDT. Perbezaan yang ketara antara parameter 
hematologi dalam kedua-dua kumpulan pesakit telah didapati di dalam kajian ini. 
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Kebanyakan pesakit di dalam kedua-dua kumpulan adalah di kalangan pesakit talasemia 
HbE/ β talasemia. Di kalangan pesakit TDT, mutasi yang paling kerap didapati adalah 
CD26 (G> A) /IVS1-5 (G> C) (28.8%), diikuti dengan CD26 (G> A) / IVS1-1 (G> T) 
(13.6%) dan CD26 (G> A) / CD41 / 42 (-TTCT) (13.6%). Manakala, di dalam kumpulan 
pesakit NTDT, mutasi yang lazim dikesan ialah IVS1-1 (G> T) dan CD19 trans kepada 
Hb E (CD26 (G> A) masing-masing sebanyak 32.4% dan 29.4%. Mutasi CD26 (G> A) / 
IVS1-1 (G> T), didapati dengan jumlah yang hampir sama untuk kedua-dua jenis 
kumpulan pesakit. Oleh itu, menunjukkan terdapat pengaruh pengubah suai genetik lain 
yang menyebabkan kepelbagaian di dalam ciri-ciri klinikal pesakit. Pesakit dengan tahap 
Hb A yang lebih tinggi semasa diagnosis mempunyai lebih rendah risiko untuk 
bergantung kepada transfusi darah (adjusted OR 0.93, 95% CI: 0.90,0.97; p <0.001), 
manakala tahap Hb F yang lebih tinggi mempunyai lebih risiko untuk bergantung kepada 
tranfusi secara berkala (adjusted OR 1.04, 95% CI:1.01,1.07, p = 0.007). Kesimpulan: 
Terdapat kepelbagaian di dalam jenis mutasi, profil hematologi dan klinikal didapati di 








CLINICO-HAEMATOLOGICAL PROFILING OF TRANSFUSION 
DEPENDENT AND NON TRANSFUSION DEPENDENT BETA 
THALASSAEMIA SYNDROME IN KEDAH 
ABSTRACT 
Introduction: β thalassaemia is a group of haemoglobin diseases caused by a reduction or 
absence in the synthesis of β globin chains. Affected individuals can be heterozygous, 
compound heterozygous, or homozygous for β thalassaemia, or even have interactions 
with other haemoglobinopathies. Kedah has a high prevalence of thalassaemia patients 
with 20.25/100000 populations. Different mutations have been identified in the β globin 
(HBB) gene generating diverse clinical phenotypes in β thalassaemia. The identification 
of the genotype is important for proper counselling to patients and their families. 
Objectives: To determine the clinical, haematology and β mutation profiling of β 
thalassaemia patients in Kedah. Methods: 100 patients with β thalassaemia were traced 
through hospital information system. A detailed clinical and laboratory records of patients 
were retrieved. For β thalassaemia genotyping, 20 different mutations were tested by 
MARMS technique. Result and Discussions: Out of 100 patients, 66% were transfusion 
dependent (TDT) and 34% of the studied patients were non transfusion dependent 
(NTDT). In this study the TDT patients had significantly lower mean age of diagnosis 
with 2.75 (2.28) years as compared to 19.87(17.87) years in NTDT (p <0.001). There was 
statistically significant presence of short stature and a larger mean size of spleen in 
patients with TDT as compared to NTDT. The significant differences between 
haematological parameters in both groups of patient were well observed in this study. 
Both NTDT and TDT group of patients were among compound heterozygous Hb E/ β 
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thalassaemia with 85.3% and 75.8% respectively. In TDT patients, the commonest 
mutations observed was CD26(G>A)/IVS1-5(G>C) (28.8%), followed with 
CD26(G>A)/IVS1-1(G>T) (13.6%) and CD26(G>A)/CD41/42(-TTCT) (13.6%).  In the 
NTDT group, the common mutations observed were IVS1-1(G>T) and CD19 trans to Hb 
E (CD26 (G>A) with 32.4% and 29.4%, respectively. It was noted in this study, diversity 
of phenotypes in patients with mutation CD26(G>A)/IVS1-1(G>T), thus indicating other 
genetic modifiers to be explored in these patients. An increment of 1 % of Hb A level at 
diagnosis have reduced odds of transfusion dependency by 7% (adjusted OR 0.93,95% 
CI: 0.90, 0.97; p<0.001) when adjusted for Hb F. Whereas, an increase in 1% of Hb F 
level, had 1.04 times higher odds to be transfusion dependent (adjusted OR 1.04,95% CI: 
1.01, 1.07, p = 0.007) when adjusted for Hb A level. Conclusion: There are diversity of 


























CHAPTER 1 : INTRODUCTION 
 General Introduction 
Thalassaemia is the most common single-gene haemoglobinopathy worldwide, and 
together with sickle cell disease, it is estimated that over 5% of the world’s population 
are carriers (Yamsri et al., 2015). It has been estimated that around 300 000 to 400 000 
babies born with severe form of this disease each year (Weatherall, 2012). 
Thalassaemia is the commonest genetic disorder in Malaysia where 3–4.5% of the Malays 
and Chinese are carriers (G Elizabeth and Ann, 2010).  There were 4768 registered 
thalassaemia patients in Malaysia reported in 2010 and between 600000 and 1000000 
carriers of the thalassaemia trait (Yatim et al., 2014). There are an estimated number of 
120 – 350 babies born with thalassaemia major each year. Kedah has a high prevalence 
of thalassaemia patients (4th highest state), with 20.25/100000 populations (Ibrahim, 
2012). Among the thalassaemia patients in Malaysia, β thalassaemia major comprises of 
44.7% whereas Hb E/β thalassaemia and β thalassaemia intermedia was 31.6% and 9.8% 
respectively, with 75% of the them were among transfusion dependent patients. This has 
become a major public health problem, with the government spending big amount of 
money for the management of the patient (G Elizabeth and Ann, 2010). According to E 
George et al, in Malaysia, management of patients with transfusion dependent 
thalassaemia has become a heavy burden for health authorities with less than 20% of 
patients received adequate iron chelation therapy and the majority of them are destined 
to decease in the second or third decade of life as result of complications of multiple organ 
failure secondary to iron overload (George, 2001).  
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β thalassaemia is a group of haemoglobin diseases caused by either reduction (β+ 
thalassaemia) or absence (β0 thalassaemia) in the production of β globin chains. The 
affected persons can be either heterozygous (β+/β or β0/β), compound heterozygous 
(β+/β0), or homozygous for beta-thalassaemia (β+/β+ or β0/β0), or even have interactions 
with other haemoglobinopathies (β+ or β0 with other Hb variant).  Their phenotypes 
include hypochromic and microcytic anaemia, elevated Hb A2 levels, and various 
syndromes as a result of the combination of β0 and β+ alleles. The pathophysiology of β 
thalassaemia comprises of ineffective erythropoiesis, peripheral haemolysis due to the 
presence of precipitation of alpha chain, and subsequent chronic anaemia and its long 
term sequelaes.  
The clinical presentation of β thalassaemia displays a broad clinical variation or 
phenotypes, ranging from a complete absence of transfusions at one end of the spectrum 
to regular transfusions at the other end.  With regard of clinical phenotype, β thalassaemia 
can be divided into three main categories: thalassaemia major (TM), thalassaemia trait 
(TT) and thalassaemia intermedia (TI). TM is the most severe form which requires 
transfusions early from infancy age for survival and also known as transfusion dependent 
thalassaemia (TDT), whereas TT is frequently asymptomatic. TI is a term used to 
represent an intermediate severity of clinical condition in between TT and TM, which 
incorporates a broad phenotypic spectrum ranging from mild anaemia to more severe 
anaemia and these patients only require occasional blood transfusions or never transfused. 
They are also being categorized as non transfusion dependent thalassaemia (NTDT), 




The different phenotypes of β thalassaemia i.e NTDT and TDT can be attributed to some 
genetic and environmental modifiers (Nadkarni et al., 2015). The inheritance of a mild β 
thalassaemia mutation which results in a residual β chain output, reduction of α chain 
synthesis due to co-inheritance of α thalassaemia or any genetic interaction that leads to 
an increased in the synthesis of foetal haemoglobin (Hb F) are among the known genetic 
modifiers causing amelioration of the clinical severity by causing reduction in the 
imbalance of α and non-α chains.  
There are more than 800 different mutations been identified and reported in the β globin 
(HBB) gene that are responsible for the β thalassaemia syndrome (Giardine et al., 2013). 
Majority of β thalassaemia are caused by point mutations, and only rarely by large 
deletion mutations. These mutations and deletions create a diversity of clinical 
phenotypes. The identification and recognition of the genotype is crucial to provide a 
proper counselling to patients and their families. Characterization of these mutations 
should aid the planning of prenatal diagnosis program for β thalassaemia.  In Malaysia 
the most common beta mutations reported are CD41/42 (–TTCT), CD26 (G>A) Hb E, 
IVS1–1 (G>T), and IVS1–5 (G>C). Among the Malays, CD26 (G>A) Hb E, CD41/42 (–
TTCT), IVS1–1 (G–T), and IVS1–5 (G–C) were the most common mutations, whereas 
CD41/42 (–TTCT) and IVS2–654 (C–T) were most common among the Chinese (Hassan 
et al., 2013).  
Hb E (βE) is one of β globin variant, occurring due to the point mutation (G>A) in codon 
26 of the β globin gene (HBB), which induced alternative splicing and resulting in 
decreased β globin E chains, and considered as β+. It is frequently seen in Southeast Asia 
countries, ranging from 10-60% for a country like Thailand, and differ from region to 
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region (Fucharoen et al., 2011). Hb E syndrome is a disorder with very heterogenous 
clinical presentation ranging from symptomless to severe clinical manifestation. 
Combination of Hb E with β thalassaemia resulting in Hb E/β thalassaemia, which is the 
most serious form of Hb E syndrome with heterogeneity in the clinical phenotypes; from 
mild anaemia to severe transfusion dependent thalassaemia major. In Peninsular 
Malaysia, studies done among transfusion dependent thalassaemia, the commonest 
genotype noted to be compound Hb E/β thalassaemia as compared to Sabah in which β 
thalassaemia major constitutes majority of the transfusion dependent thalassaemia (Teh 
et al., 2014). 
The diagnosis of β thalassaemia in Hospital Sultanah Bahiyah (HSB) is based on 
parameters acquired from the clinical findings, blood picture and haemoglobin analysis. 
Haemoglobin analysis were performed by using Capillary Electrophoresis (CE) method, 
supplemented with other second method i.e. High Performance Liquid Chromatography 
(HPLC) or alkaline gel electrophoresis. Further molecular characterization or β globin 
gene analysis is suggested for patients with borderline Hb A2, delta beta 
thalassaemia/Hereditary Persistence Haemoglobin F, suspected β variants, β thalassaemia 
intermedia and major as well as cases with Hb E/β thalassaemia. The molecular study is 
performed in the reference laboratory i.e. Institute Medical Research (IMR). Regrettably  
not all patients with diagnosis of beta thalassaemia major/intermedia/ Hb E/β 
thalassaemia are supported by the molecular analysis.  
With the current aggressive structured school based screening programme which started 
in 2016 by the Ministry of Health, it is important that a clear molecular pathology of the 
disease can be ascertained and appropriate management can be done. Thus by knowing 
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the clinical, haematological as well as the different mutations in both transfusion and non-
transfusion dependent thalassaemia may help in predicting the severity of the disease as 
well as establishing the appropriate screening program for thalassaemia syndrome.  
 
 Problem Statements & Study Rationale 
Kedah, being a Northern state in Malaysia and bordered with Southern Thailand, has a 
relatively high incidence of both β thalassaemia and haemoglobinopathy (Hb E) that has 
been considered a known public health problem. The molecular aspect of β thalassaemia 
mutation in Kedah state has never been analysed before in relation to the different clinical 
phenotypes (TDT and NTDT).   
The aims of this study are to determine the clinical features, haematology as well as β 
mutation profiles of β thalassaemia patients in Kedah state. The patients will be classified 
into 2 groups which are transfusion dependent and non- transfusion dependent by using 
certain criteria which is the frequency of blood transfusions per year.  It is also aimed to 
characterize the haematology and β mutation profiles among the two groups and trying 
to see the association of the type of molecular characteristic affecting the disease severity. 
It is also hoped that by knowing the certain haematological parameters, it can help the 
clinicians in predicting the severity of the phenotype in a newly diagnosed β thalassaemia 
patients and thus helps in managing them accordingly. 
There are more than 800 different mutations have been reported and identified in the β 
globin (HBB) gene which are responsible for the development of the β thalassaemia 
(Giardine et al., 2013). By identifying the commonest β thalassaemia mutations in a 
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certain population, it will assist in a simpler subsequent diagnostic approach, more cost 
effective and more rapid by concentrating on the small number alleles which are 
predominant in different ethnic, rather than focusing on a wide range of rare uncommon 
alleles. As the occurrences of different β thalassaemia alleles vary significantly with 
geographic location and ethnicity (Yatim et al., 2014), this study is performed to 
characterise β thalassaemia mutations at the molecular level among patients from Kedah, 
a northern state of Peninsular Malaysia as being near Thailand border, might have 
different beta gene mutation compared to study done in other settings in Malaysia.  
It is also hoped that by knowing any genotype and phenotype associations, it can be 
utilised for improvement of management protocols, i.e. blood transfusions and iron 
chelation as well as also provides the potential for molecular therapies and improve 
























CHAPTER 2 : LITERATURE REVIEW 
 Structure and Genetics of Haemoglobin 
Haemoglobin is a major protein molecule in RBC, playing a very crucial role in oxygen 
transportation from the lungs to all tissues in the body. It is comprised of two pairs of 
polypeptide chain i.e. a pair of α globin chain and β globin chain, with one haem molecule 
will be inserted to each pair, which are crucial for the accommodation of oxygen 
transportation (Bain, 2011). 
There are different haemoglobins present during embryo life, foetus and adulthood, each 
adapted according to the particular oxygen requirement. Hb Portland, Hb Gower 1 and 
Hb Gower 2 are the haemoglobins present during embryonic life, whereas Hb F 
predominates in the foetus. Hb A (α2β2), constitutes over 95% of the total haemoglobin 
in adult, with a minor proportion of adult haemoglobin is constituted by Hb A2 (α2δ2) and 
Hb F(α2γ2). The difference in the types of haemoglobin is due to the adaptation for the 
physiological requirement that occur during the development. Foetal haemoglobin (α2γ2) 
has a higher affinity for the oxygen as compared to the adult type, thus facilitates the 
oxygen transfer via the placenta from the maternal to the foetal circulation (A Victor 
Hoffbrand, 2016).  Yolk sac is the main site of production of haemoglobin at the initial 
stage of embryonal period, followed by liver and spleen during 10th to 12th week of 
gestation, and later bone marrow will gradually take place as the primary site for the 






Figure 2.1: The timelines of expression of human globin gene (adapted from 
Postgraduate Haematology 7th edition, 2016) 
 
Each of the α-like and β-like globin is encoded by genetically distinct loci, with α-like 
clusters are on the tip of chromosome 16p whereas the β-like globin gene is on 
chromosome 11p15.5. The genes are arranged along the chromosomes according to the 
sequence in which they are expressed during the development: 5′-ε-Gγ-Aγ-ψβ-δ-β-3′ and 
5′-ζ-ψζ-ψα2-ψα1-α2-α1–3′. The ψβ, ψζ and ψα-genes are pseudogenes, in which they 
have sequences that bear a resemblance to the β, ζ or α-genes, but contain inactivating 
mutations that render them non-expressed (A Victor Hoffbrand, 2016). The globin genes 
have either one or more of the non-coding inserts, which is called intervening sequences 
(IVS) or also known as introns which intersecting the coding sequences or exons (A 




The β globin genes have three exons which are interrupted by the two introns of 122-130 
and 850-900bp.  This β genomic sequence encoded for 146 amino acids with intron 1 
interferes the sequence between codons 30 and 31, whereas intron 2 between codons 104 
and 105. Meanwhile, the α globin genes encoded for 141 amino acids and contain smaller 
introns between codons 30 and 31 and between codons 99 and 100 (A Victor Hoffbrand, 
2016) (Figure 2-2) 













Figure 2.2: (a) and (b) showed the structure of α-globin gene and β globin gene. 
Adapted from (Passarge,2007) 
 
The gene expression control occurs at multiple levels, but commonly at the transcriptional 
level. Other gene regulations also occurred during as well as after translational period. 
Besides the primary cis determinants of individual globin gene expression within each α 
and β globin complex, which are situated in the immediate vicinity and within each gene, 
there are also other local regulatory elements which better known as enhancers, situated 
at different distances from each individual gene.(A Victor Hoffbrand, 2016). The local 
cis-acting sequences which control globin gene expression include the promoter region, 
splicing donor and acceptors, as well as poly-A addition sites (A Victor Hoffbrand, 2016). 
The promoter, which is located in the 5′ flanking region, includes nucleotide homology 
blocks that are found in analogous positions in many other species (Thein, 2013). The 
three positive cis-acting elements comprise of the TATA box (position −28 to −31, i.e. 





between 28 and 31 bases upstream from the mRNA ‘cap’ site), a CCAAT box (position 
−72 to −76), and a CACCC motif which may either be duplicated or inverted (position 
−80 to −140). The transcription factors will recognise these promoter elements and are 
responsible for the transcription initiation (Thein, 2013) (Figure 2-3). 
 
 
Figure 2.3 : A schematic presentation of prototype globin gene and the genetic control 
of globin chain synthesis (adapted from Postgraduate Haematology Seventh Edition,(A 




 Introduction of Thalassaemia/Haemoglobinopathy 
The thalassaemia is a heterogeneous group of haemoglobin disorder, which is 
characterized by the reduction in the synthesis (quantitative disorder) of one or more 
globin chains. Types of thalassaemia can be divided in accordance to the affected globin 
chains, namely α, β, δβ, δ or γ with the most common type of thalassaemia are α and β 
thalassaemia (A Victor Hoffbrand, 2016). 
Haemoglobinopathy are characterized by the qualitative changes of the haemoglobin 
produced, which may include unstable haemoglobin, decreased in oxygen affinity etc. 
Among the commonest types of haemoglobinopathy includes Hb S, Hb E, Hb C, etc, with 
different prevalent in between regions (Rees et al., 1998). 
 
Thalassaemia is the commonest single gene disorders in the world, with about 4% of the 
human populations worldwide carry a gene for either thalassaemia or haemoglobinopathy 
(Ahmed, 2017).  Among the earliest thalassaemia case reported was back in 1938 from 
Indian subcontinent (Weatherall, 2012). 
 
Mutations in the globin genes may lead to the either reduction in the production of the 
protein or to the alteration in the sequence of amino acid of the protein, or mixture of two 
(A Victor Hoffbrand, 2016). Quantitative defects result in thalassaemia syndromes. The 
types of thalassaemia can be segregated in accordance to the affected type of globin chain, 
which are α, β, δβ, γδβ, δ, or γ. However, the most common types of thalassaemia reported 
are α and β. The qualitative changes or also referred as haemoglobin variants, cause a 
varied range of problems, among all are sickle cell disease, unstable haemoglobins, 
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decreased or increased oxygen affinity as well as methaemoglobinaemia (A Victor 
Hoffbrand, 2016). Some of the mutations may result in the mixture of quantitative and 
qualitative defects; resulting in a haemoglobin variant that is produced in a reduced 
amount, with the most common example is Hb E (A Victor Hoffbrand, 2016). 
 
Alpha (α) thalassaemia is caused by either absence or reduced in production of the α 
globin chain. Majority of α thalassaemia is due to gene deletions and rarely caused by 
point mutations. It has been reported to be prevailing in many countries in South East 
Asia, with gene frequencies reported to be 16-30% in Thailand, 5% in Philippines, 2.6-
11% in Indonesia, 4.3% in Brunei and 4.1% in Malaysia (Ahmad et al., 2013). Alpha 
thalassaemia can be regarded on as a spectrum of conditions reflecting gene dosage 
effects, which result from the loss of function of different numbers of α globin genes 
(Kleanthous and Phylactides, 2008). They are categorised into two classes: αo 
thalassaemia, in which both α globin genes are inactivated, and α+ thalassaemia, in which 
only one of the two α globin genes on chromosome 16 is defective or inactivated. The 
spectrum of diverse clinical disorders of α thalassaemia correlates well with the number 
of affected α globin genes (Kleanthous and Phylactides, 2008).  
 
β thalassaemia on the other hand is due to the reduction or absence of the production of 
β globin chain. Differ from α thalassaemia, point mutation and small insertion/deletions 
of one or two bases on the β globin gene are the main causes for the β thalassaemia, with 




Most thalassaemia is inherited in a Mendelian recessive way. Heterozygotes are mostly 
asymptomatic, although frequently they can be identified through a simple 
haematological analysis. More severely manifested patients are either homozygotes for α 
or β thalassaemia or compound heterozygotes for different molecular forms of α or β 
thalassaemia or for one or other form of thalassaemia and a gene for a haemoglobin 
variant (Brancaleoni et al., 2016). 
 
Clinically, the thalassaemia is categorized based on the severity into major, intermediate 
as well as minor forms. Thalassaemia major is a severe and transfusion dependent 
disorder whereas thalassaemia minor is the asymptomatic trait or carrier state(A Victor 
Hoffbrand, 2016). Thalassaemia intermedia embrace a wide spectrum of clinical 
severities intermediate between thalassaemia major and trait. Thalassaemia intermedia, 
which also known as non transfusion dependent thalassaemia (NTDT) remains as a 
clinical definition and comprises of β thalassaemia intermedia, Hb H disease and the Hb 
E/β thalassaemia (A Victor Hoffbrand, 2016; Danjou et al., 2011). 
 
Table 2.1: Classification of thalassaemia 
Type of thalassaemia Chain or chains 
synthesised at reduced 
rate 
Haemoglobin/s 
synthesised  at reduced 
rate 
Alpha:α α A, A2 and F 
Beta:β Β A 
Gamma:γ γ F 
Delta:δ δ A2 




 β Thalassaemia 
 Epidemiology 
β thalassaemia is a group of genetic disorder that results in either reduced or absent 
production of β globin protein. It is due to mutation in the β globin gene (HBB) on 
chromosome 11. Up to the present time, there are more than 800 mutations and 
haemoglobin variants have been identified (Giardine et al., 2013), but according to the 
population studies, indicate that only about 40 mutations account for 90% of the β 
thalassaemia worldwide (Flint et al., 1998).  
Based on WHO report in 2008, β thalassaemia is the second most prevalent of 
haemoglobin disorder after sickle cell disease. Globally, it is estimated to be 1.5% (80-
90 million) of people throughout the world is β thalassaemia carrier and about 60000 
infants with carrier status are born annually (Kyrri et al., 2013); (Galanello and Origa, 
2010).  Flint J et al in 1998 has found that incidence of β thalassaemia is highest in 
Mediterranean, North coast of Africa, South American, Central Asia, Middle east, India 
as well as Southern China. The carrier rate is higher in Cyprus (14%), followed by 
Sardinia and South East Asia (Flint et al., 1998).  
In Malaysia, the approximated carrier rate for β thalassaemia is between 3.5-4% (G 
Elizabeth and Ann, 2010).  Kedah is one of the state in Malaysia with high prevalent of 
thalassaemia (4th highest state), with 20.25/100000 populations (Ibrahim, 2012). 
 
 Genetic basis of β thalassaemia 
β globin is encoded by a gene found in a cluster with the other β like genes on the short 
arm of chromosome 11. The genomic sequence codes for 146 amino acids with the 
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transcribed region is confined in 3 exons which are separated by the two introns or 
intervening sequence (IVS). Exon 1 and 3 encode for the non-haem binding regions of 
the β globin chain whereas the residues that involved in haem binding and αβ dimer 
formation are encoded by exon 2 (Thein, 2005). 
 
β thalassaemia results from the quantitative reduction of β globin chain synthesis which 
may lead to either reduced or absence of Hb A (α2β2) level. This is frequently caused by 
diverse mutations occurred on β globin gene (HBB). Most of the defects are the 
consequences of point mutations or a small deletion which results in the reduction or 
absence of β globin chain synthesis. This mutation or deletions may involve all the steps 
from the transcription of the DNA, processing of the mRNA transcript, translational or 
post-translational stability of the globin gene product. Majority of the mutations are point 
mutation with either small insertion, deletion, or single base substitution which involve 
the 5’ and 3’ flanking untranslated regions (UTR) sequences or at promoter region, exon, 
intron, intron-exon boundaries, and polyadenylation sites of HBB gene (Hanafi et al., 
2017). The difference in the mutations may either result in completely inactivated β gene 
with absence of β globin production (β0-thalassaemia) or may allow some production of 
β globin results in β+- or β++-thalassaemia, either marked or mild reduction in the β-chains 
output, respectively (A Victor Hoffbrand, 2016; Danjou et al., 2011). The mild β 
thalassaemia (β++) alleles are associated with a mild change in heterozygotes and 
disorders of intermediate severity among homozygotes (Thein, 2004). Meanwhile, 
interactions with the other severe alleles are less predictable in view of the broader range 
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of β globin output, and may range from transfusion dependence to intermediate forms of 
β thalassaemia (Camaschella et al., 1995; Thein, 2004).  
 
There are also mutations known as the ‘silent’ β thalassaemia, where the deficit in β chain 
production is very minimal. The carriers may have either minimally reduced or even 
normal red cell indices and their Hb A2 levels are within normal range (Thein, 2004). 
These ‘silent’ mutations are typically identified in the compound heterozygous states with 
other severe β thalassaemia allele, resulting in thalassaemia intermedia phenotypes or 
presented with a typical phenotype of β thalassaemia trait in homozygotes (Thein, 2013). 
This ‘silent’ β thalassaemia alleles are very uncommon, except for the -101 C–T, which 
contribute for a great number of the milder phenotypes of β thalassaemia in the 
Mediterranean region (Maragoudaki et al., 1999; Thein, 2004).   
 
Patients with genotype β0/β0 normally manifested with severe clinical presentation and 
are known as thalassaemia major whereas patients with genotype of β+/ β0 or β+/ β+ 
usually have diverse clinical severities and known as thalassaemia intermedia. Individual 
with β/ β0 or β/ β+ is known as thalassaemia trait and usually with no clinical significance 
(Thein, 2005). 
 
The mutations of the β globin gene vary in between the regions. In Turkey, CD8 (-AA), 
IVS1-6(T>C) and IVS 2-1(G>A) are the commonest reported, whereas in Egypt (IVS1-
1, IVS1-110 and IVS1-6 were the commonest reported mutations (Fettah et al., 2013). In 
South East Asia, studies done in Thailand showed that the deletion at CD41/42 (-TCTT) 
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was the most frequent (48%) mutations. Other mutations found in order of decreasing 
frequency were CD17 (A>T) (30%), -28 (A>G) (6%) IVS1-1(G>T) (6%), A -87 (C>A) 
(4%), IVS2-654 (C>T) (2%), CD71/72 (+A) (2%) and CD35 (C>A) (2%), respectively 
(Mirasena et al., 2013).  
 
In Malaysia the commonest β mutations reported are CD41/42 (–TTCT), CD 26 (G>A) 
Hb E, IVS1–1 (G>T), and IVS1–5 (G>C). Among the Malays, CD26 (G>A) Hb E, CD 
41/42 (–TTCT), IVS1–1 (G>T), and IVS1–5 (G>C) were the commonest mutations, 
whereas CD41/42 (–TTCT) and IVS2–654 (C–T) were most common among the Chinese 
(G Elizabeth and Ann, 2010). In a study done in Penang by Nur Fatihah Mohd Yatim et 
al, where they molecularly characterise 20 different β thalassaemia mutations in 40 
unrelated Malays, the highest prevalence of beta thalassaemia alleles among Malays from 
Penang is βE mutation (Yatim et al., 2014). Figure 2.4 illustrates the schematic 
presentation of mutations in the HBB gene. 
 
 





 Haemoglobin E (Hb E) 
Hb E (α2β2
26(Glu-Lys) is one of the structural haemoglobin variant due to substitution of the 
glutamine by lysine at codon 26 of β globin gene due to the point mutation. It was 
described for the first time in 1950s by Chernoff and his colleague (Moiz et al., 2012). 
The frequency of the disease differs in lines with different ethnicity and geographical 
area. South East Asia (SEA) regions is reported to have a highest prevalent of Hb E, 
ranging from 5-10% and may reached up to 50% in countries like Thailand and Cambodia 
(Ruengthanoo et al., 2017). In Malaysia, Hb E (βE) is among the most common β mutation 
found especially in Malay populations (G Elizabeth and Ann, 2010). It is believed that 
Hb E gives protection against malarial infection, and thus may explained the high 
prevalence in South East Asia countries (Moiz et al., 2012).  
 
The substitution of the base at codon 26 of β globin gene, GAG>AAG at exon 1, leads to 
alteration of Glutamic acid to Lysine. This abnormal gene (βE-globin gene, HBB:c.79 
G>A) produces a structurally abnormal Hb consisting of α2βE2-globin chains. In addition 
to that, the abnormal sequence also activates a cryptic 5’ splice site which leads to 
abnormal pre-mRNA splicing. The normal donor splice site will compete with the new 
cryptic splice site and consequently results in the reduction of the level of correctly 
spliced βE-globin mRNA while the aberrant splicing leads to a 16 nucleotide deletion of 
the 3’ end in exon I , creating a new in frame stop (Figure 2-5) (Tubsuwan et al., 2011).  
As a result, Hb E is produced at a reduced rate and the βE-globin gene results in symptoms 
similar to a mild form of β-thalassaemia (Tubsuwan et al., 2011). Thus, the phenotype 
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for Hb E is behaved as β+.   Heterozygous as well as homozygous Hb E is typically 
symptomless with microcytic hypochromic mild anaemia.  
 
In view of high frequency of different β thalassaemia alleles as well as different forms of 
alpha thalassaemia in SEA regions, coinheritance of Hb E/ β and Hb E/α, occurs very 
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Figure 2.5: Illustration of aberrant splicing of βE-globin mRNA. Black box denotes 16 
nucleotides at the 3’ exon 1 deleted by the aberrant splicing. Adapted with modification 
from (Tubsuwan et al., 2011)  




 Haemoglobin  Malay (Hb Malay (βMALAY) 
Hb Malay is one of the β variant that was described firstly in 1989 in Malaysia, as a result 
of an investigation of anaemia in a 22-year-old Malay gentleman who was homozygous 
for this variant. This Hb variant is caused by AAC > AGC mutation at codon 19 of the β 
globin gene which results in the exchange of serine for asparagine. This mutation 
produces a cryptic RNA splice site in exon 1 of the β globin gene which leads to an 
abnormal RNA processing. Thus, this mutation not only yields variant haemoglobin but 
also results in a mild β+ thalassemia phenotype (Amran et al., 2018).  
A study done by IMR showed the prevalence of Hb Malay in Malaysia population was 
5.5% with the majority of the cases were among Malays, 127/132 (96.2%), followed by 
Dusun, 2/132 (1.5%), Chinese, 1/132 (0.8%), Bajau, 1/132 (0.8%) and Orang Asli, 1/132 
(0.8%) (Yusoff et al., 2018). Majority of them were heterozygous Hb Malay (83/132) 
with 27/132 were compound heterozygous Hb Malay/Hb E, 8/132 were compound 
heterozygous Hb Malay/β⁺ thalassaemia, 7/132 were compound heterozygous Hb 
Malay/β0 thalassaemia 4/132 followed with other combinations with other 
thalassemia/haemoglobinopathy(Yusoff et al., 2018).   
Both high performance liquid chromatography (HPLC) for haemoglobin variant as well 
as capillary zone electrophoresis (CE) cannot discriminate between Hb A and Hb Malay 
as it is co-migrated (Yusoff et al., 2018). Thus, the definitive diagnosis of Hb Malay can 
solely be made by molecular analysis (Yusoff et al., 2018). 
In the heterozygous state, Hb Malay can be missed as normal study or borderline HbA2, 
as it is co-eluted with Hb A. Simple heterozygotes for Hb Malay have mild microcytosis 
and elevated/borderline Hb A2 levels, identical to the other β-thalassemia carriers (Ma et 
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al., 2000).  Individuals with either homozygous for Hb Malay or compound heterozygous 
for Hb Malay and Hb E have Hb levels around 90–100 g/l, significant microcytosis with 
MCV of approximately 60fl, and elevated Hb F levels from 12 to 32% (Ma et al., 2000). 
There were case reports and case series regarding diversity in phenotypes in homozygous 
Hb Malay as well as compound heterozygosity of Hb Malay with other β+/β0 or with HbE 
(βE).  Fucharoen in 2001, had described 2 cases of thalassaemia intermedia in two 
adolescents with homozygous Hb Malay (βMALAY/ βMALAY) and compound heterozygous 
Hb Malay and HbE (βMALAY/ βE) (Fucharoen et al., 2001).  A case series of 12 Thai 
patients with compound heterozygosity for Hb Malay and either β+ (IVS I-5 G→C) or β0 
thalassemia mutations (CD 17 (A→C), CD 41/42(-C), and 3.4-kb deletion) were reported 
back in 1997.  These patients presented with severe anaemia with Hb levels as low as 42 
g/l, presence of hepatosplenomegaly, and required regular blood transfusions, similar 
with β thalassaemia major patients. Most of them also had raised Hb F levels, up to 46% 
or more. In 1991, a 4-year old Thai girl with compound heterozygosity for Hb Malay and 
a β0 thalassaemia mutation, codon 41 (-C), was noted to be severely anaemic with a Hb 
of 24 g/l. Another patient with Hb Malay/codon 41 (-C) had been described with Hb 52 
g/l, MCV of 84 fl, and an Hb F level of 3.2% (Laosombat et al., 1997). In these patients, 
since Hb Malay is indistinguishable from Hb A on electrophoresis, it is possible that these 
patients might be misdiagnosed as simply heterozygous carriers of β thalassaemia 
mutation based on Hb analysis alone. In Malaysia, a total of 12 cases of confirmed 
heterozygous, homozygous or compound heterozygous of Hb Malay were studied and 
noted 3/12 patient with βMALAY/β+ presented with moderate anaemia and splenomegaly 
and required irregular blood transfusion during pregnancy or during acute illness (Amran 
